SpliceBio is a clinical-stage genetic medicines company specializing in Protein Splicing technology to treat diseases caused by mutations in large genes. The company is advancing its lead program, SB-007, for Stargardt disease and is developing a broader pipeline targeting indications in ophthalmology, neurology, and other therapeutic areas.
Leadership & Board
Current Number of Employees59
Current LinkedIn Followers11,661
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$135M
Total Amount Raised$135M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$135M
Latest Funding Amount$135M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
SpliceBio had 59 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
59Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
SpliceBio had 11,661 followers as of September 7, 2026. The number of followers increased by 52 (0.45%) week-over-week.
11,661Latest Followers Count
52(0.45%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.